AmpliPhi Signs Exclusive License With University of Leicester, UK

News   Oct 18, 2013

 
AmpliPhi Signs Exclusive License With University of Leicester, UK
 
 
 

RELATED ARTICLES

‘Bad’ Antibodies Provide Crucial Protection Against Invading Microbes

News

In a world first, scientists have revealed how a population of 'bad' antibodies in the immune system - which are usually 'silenced' because they can harm the body - can provide crucial protection against invading microbes.

READ MORE

Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas

News

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.

READ MORE

Drug Combo Improves Survival of Women with Rare Uterine Cancer

News

Adding the monoclonal antibody drug trastuzumab - already used to treat certain breast cancers - to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small Phase II trial of the regimen, testing its safety and value.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE